Breaking News Instant updates and real-time market news.

TXMD

TherapeuticsMD

$5.10

-0.045 (-0.88%)

04:55
01/24/19
01/24
04:55
01/24/19
04:55

TherapeuticsMD management to meet with Oppenheimer

Meetings to be held in New York on January 23 and in Boston on January 24 hosted by Oppenheimer.

  • 24

    Jan

TXMD TherapeuticsMD
$5.10

-0.045 (-0.88%)

08/23/18
STFL
08/23/18
NO CHANGE
Target $20
STFL
Buy
TherapeuticsMD a 'rare early commercial story' in womens health, says Stifel
Stifel analyst Annabel Samimy kept her Buy rating and $20 price target on TherapeuticsMD, saying her recent meetings with the management focused on its launch of Imvexxy for VVA. The analyst notes that its early metrics are strong with over 2.4K prescriptions filled within weeks, adding that the product has "multiple ways to win" thanks to its win-affordability, education, and superiority.
10/03/18
CANT
10/03/18
NO CHANGE
Target $27
CANT
Overweight
Cantor says TherapeuticsMD should have 'ample cash' through end of 2019
Cantor Fitzgerald analyst William Tanner believes some investors connected two of his prior comments about TherapeuticsMD disclosing ongoing labeling talks with the FDA regarding TX-001 and his foreseeing that the company would need to raise capital in the future and "jumped to" the conclusion that the company would raise capital after TX-001 approval, assuming that occurs. However, in an updated corporate presentation, the company noted a cash balance of $154.4M at the end of Q2 and Tanner projects cash of about $70M at the end of 2019 before the company becomes cash flow positive in the beginning of 2020. Tanner also noted that management has explained that their labeling talks disclosure was meant to take the topic off the table and prevent "awkward conversations" at Cantor's healthcare conference. The analyst, who now believes he was "dead wrong" in his assumption that the FDA talks disclosure may have been made to get "the stock moving," reiterates an Overweight rating and $27 price target on TherapeuticsMD shares.
12/11/18
CANT
12/11/18
NO CHANGE
Target $27
CANT
Overweight
FDA report highlights large opportunity for TherapeuticsMD, says Cantor
In a research note titled "Not Too Hot, Not Too Cold, Things Are Just Right at TXMD," Cantor Fitzgerald analyst Louise Chen keeps an Overweight rating on TherapeuticsMD with a $27 price target. The FDA released its "2018 Compounding Policy Priorities Plan," which underscores the "large and underappreciated" market opportunity for TherapeuticsMD' Bijuva, Chen tells investors in a research note. She points out that one of the priorities listed by the FDA includes: "Restricting Compounding of Drugs that are Essentially Copies of FDA-Approved Drugs." This is positive for Bijuva, says Chen. The analyst thinks the peak sales potential for the drug is $1B-plus.
01/07/19
CANT
01/07/19
NO CHANGE
Target $27
CANT
Overweight
TherapeuticsMD shares underappreciate three launches, says Cantor Fitzgerald
In a research note titled "I'm Vexxyed By TXMD's Stock Price," Cantor Fitzgerald analyst Louise Chen reaffirms an Overweight rating on TherapeuticsMD with a $27 price target. The execution of the Imvexxy, Bijuva and Annovera launches is underappreciated, Chen tells investors. She thinks peak sales could exceed "modest expectations for the three drugs that target large unmet needs." Discussions with two experienced OB-GYNs that have already prescribed Imvexxy and are excited to prescribe Bijuva and Annovera support a positive investment thesis on the stock, adds the analyst.

TODAY'S FREE FLY STORIES

DXCM

DexCom

$139.14

-7.14 (-4.88%)

13:17
02/22/19
02/22
13:17
02/22/19
13:17
Hot Stocks
DexCom receives Health Canada approval for G6 CGM System »

Dexcom announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
02/22/19
02/22
13:17
02/22/19
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
02/22/19
02/22
13:16
02/22/19
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PSTG

Pure Storage

$19.90

0.33 (1.69%)

13:15
02/22/19
02/22
13:15
02/22/19
13:15
Options
Pure Storage put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 28

    Feb

  • 13

    Mar

13:15
02/22/19
02/22
13:15
02/22/19
13:15
General news
Breaking General news story  »

Philadelphia Federal…

13:15
02/22/19
02/22
13:15
02/22/19
13:15
General news
Breaking General news story  »

US Federal Reserve Bank…

13:15
02/22/19
02/22
13:15
02/22/19
13:15
General news
Breaking General news story  »

St. Louis Federal Reserve…

CGC

Canopy Growth

$44.32

-0.67 (-1.49%)

13:14
02/22/19
02/22
13:14
02/22/19
13:14
Hot Stocks
Canopy reverses decline after CEO talks asset possibilities with Bloomberg »

Shares of Canopy Growth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BHGE

Baker Hughes

$26.29

0.01 (0.04%)

13:03
02/22/19
02/22
13:03
02/22/19
13:03
Hot Stocks
Baker Hughes reports U.S. rig count down 4 to 1,047 rigs »

Baker Hughes reports that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Mar

  • 22

    May

  • 28

    May

EFX

Equifax

$110.23

-0.28 (-0.25%)

13:00
02/22/19
02/22
13:00
02/22/19
13:00
Hot Stocks
Equifax says U.S. regulators seek damages related to 2017 breach »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

BILI

Bilibili

$19.48

1.34 (7.39%)

13:00
02/22/19
02/22
13:00
02/22/19
13:00
Options
Bullish option flow in Bilibili as shares rally 7% ahead of earnings »

Bullish option flow in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

VALE

Vale

$12.45

0.43 (3.58%)

12:57
02/22/19
02/22
12:57
02/22/19
12:57
Periodicals
Federal prosecutors in Brazil seek arrest of senior Vale exec, Reuters reports »

Federal prosecutors in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KHC

Kraft Heinz

$34.99

-13.2 (-27.39%)

, K

Kellogg

$56.53

-1.8 (-3.09%)

12:57
02/22/19
02/22
12:57
02/22/19
12:57
Periodicals
Prescience Point sees Kellogg following Kraft Heinz with dividend cut »

Short seller Prescience…

KHC

Kraft Heinz

$34.99

-13.2 (-27.39%)

K

Kellogg

$56.53

-1.8 (-3.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 03

    Mar

SNAP

Snap

$9.74

0.35 (3.73%)

12:50
02/22/19
02/22
12:50
02/22/19
12:50
Options
Snap calls active as shares see strength »

Snap calls active as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

UBNK

United Financial

$16.11

0.02 (0.12%)

12:49
02/22/19
02/22
12:49
02/22/19
12:49
Hot Stocks
FJ Capital reports 6.47% passive stake in United Financial »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KPTI

Karyopharm

$7.49

-1.47 (-16.41%)

12:48
02/22/19
02/22
12:48
02/22/19
12:48
Hot Stocks
Karyopharm drops 40% after FDA posts Selinexor meeting briefing docs »

Shares of Karyopharm are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 28

    Feb

  • 06

    Apr

HK

Halcon Resources

$1.67

-0.12 (-6.70%)

12:47
02/22/19
02/22
12:47
02/22/19
12:47
Hot Stocks
Fir Tree comments on Halcon CEO departure, renews call for sale of company »

Fir Tree Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:45
02/22/19
02/22
12:45
02/22/19
12:45
General news
Breaking General news story  »

Week of 2/22 Baker-Hughes…

KPTI

Karyopharm

$8.97

0.01 (0.11%)

12:43
02/22/19
02/22
12:43
02/22/19
12:43
Hot Stocks
Breaking Hot Stocks news story on Karyopharm »

Karyopharm trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 28

    Feb

  • 06

    Apr

CMCSA

Comcast

$38.53

0.065 (0.17%)

, CMCSK

Comcast

$0.00

(0.00%)

12:43
02/22/19
02/22
12:43
02/22/19
12:43
On The Fly
Box Office Battle: 'How to Train Your Dragon' sequel flies into theaters »

Welcome to "Box Office…

CMCSA

Comcast

$38.53

0.065 (0.17%)

CMCSK

Comcast

$0.00

(0.00%)

FOX

21st Century Fox

$50.68

0.22 (0.44%)

FOXA

21st Century Fox

$50.97

0.23 (0.45%)

T

AT&T

$31.02

0.19 (0.62%)

DIS

Disney

$115.18

0.88 (0.77%)

LGF.A

Lionsgate

$15.49

0.15 (0.98%)

LGF.B

Lionsgate

$14.65

0.16 (1.10%)

SNE

Sony

$48.02

0.37 (0.78%)

VIA

Viacom

$34.75

(0.00%)

VIAB

Viacom

$29.44

0.25 (0.86%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 27

    Feb

  • 03

    Mar

  • 04

    Mar

  • 04

    Mar

  • 07

    Mar

  • 11

    Mar

  • 11

    Mar

  • 11

    Mar

  • 20

    Mar

  • 06

    Jun

KPTI

Karyopharm

$9.03

0.07 (0.78%)

12:42
02/22/19
02/22
12:42
02/22/19
12:42
Hot Stocks
Breaking Hot Stocks news story on Karyopharm »

Karyopharm trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 28

    Feb

  • 06

    Apr

KPTI

Karyopharm

$9.03

0.07 (0.78%)

12:39
02/22/19
02/22
12:39
02/22/19
12:39
Hot Stocks
Breaking Hot Stocks news story on Karyopharm »

Karyopharm drops 16.5%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 28

    Feb

  • 06

    Apr

ATVI

Activision Blizzard

$41.62

-0.28 (-0.67%)

, TTWO

Take-Two

$86.50

-1.08 (-1.23%)

12:37
02/22/19
02/22
12:37
02/22/19
12:37
Periodicals
FTC plans public workshop to go over loot boxes in video games, Verge reports »

The Federal Trade…

ATVI

Activision Blizzard

$41.62

-0.28 (-0.67%)

TTWO

Take-Two

$86.50

-1.08 (-1.23%)

EA

Electronic Arts

$94.44

-2.39 (-2.47%)

UBSFY

Ubisoft

$0.00

(0.00%)

TCEHY

Tencent

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 12

    Mar

  • 13

    Mar

  • 21

    Mar

KPTI

Karyopharm

$9.03

0.07 (0.78%)

12:35
02/22/19
02/22
12:35
02/22/19
12:35
Hot Stocks
Karyopharm quickly drops 16.5% »

Shares of Karyopharm have…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 28

    Feb

  • 06

    Apr

KPTI

Karyopharm

$9.04

0.08 (0.89%)

12:32
02/22/19
02/22
12:32
02/22/19
12:32
Hot Stocks
Breaking Hot Stocks news story on Karyopharm »

Karyopharm trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 28

    Feb

  • 06

    Apr

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.